Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
ID: 349504Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349504

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at developing and testing enhanced models of care that integrate HIV, addiction, and primary care services. This initiative seeks to improve health outcomes for individuals at heightened risk for HIV, Hepatitis B and C, and substance use disorder (SUD) by addressing service delivery gaps influenced by social barriers such as stigma and discrimination. Eligible applicants include a diverse range of organizations, including higher education institutions, non-profits, and foreign entities, with a total funding amount of $2 million anticipated across the R01 and R34 mechanisms for projects lasting up to five years. Interested parties must submit their applications by March 20, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-019-Full-Announcement.html
    RFA-DA-25-019.html
    The National Institutes of Health (NIH) is offering funding through a Notice of Funding Opportunity (NOFO) aimed at integrating HIV/AIDS, addiction, and primary care services. Under the funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," research proposals are sought to develop and test enhanced models of care. The initiative specifically targets the coordination of services to improve health outcomes for individuals at heightened risk for HIV, Hepatitis B and C, and substance use disorder (SUD). The funding opportunity emphasizes comprehensive and integrated care models, addressing gaps in service delivery influenced by social barriers like stigma and discrimination. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, state and local governments, and foreign entities. The application process requires adherence to strict guidelines and has a maximum project period of five years with a total of $2 million anticipated across the R01 and R34 mechanisms. This funding aims to support innovative research aligned with the "Ending the HIV Epidemic: A Plan for America" initiative, particularly in areas demonstrating high HIV burden. The deadline for application submissions is March 20, 2025, marking a critical opportunity for impactful research in integrated health services.
    Similar Opportunities
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting R01 Clinical Trials. This initiative seeks to develop and evaluate innovative care models that effectively integrate services for HIV/AIDS, substance use disorders (SUD), and optional hepatitis, with the goal of enhancing healthcare delivery and improving health outcomes for affected individuals. The program aligns with the "Ending the HIV Epidemic: A Plan for America" initiative and emphasizes the importance of coordinated care in settings such as Federally Qualified Health Centers. Eligible applicants include various institutions and organizations, with an expected award budget of up to $2 million for fiscal year 2026 and a project duration of up to five years. Interested parties can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by March 19, 2025.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)." This initiative aims to support the development and testing of innovative care models that integrate HIV, addiction, and primary care services to improve health outcomes, particularly for individuals at heightened risk of HIV and those living with HIV alongside substance use disorders. The program is part of the broader "Ending the HIV Epidemic" plan, emphasizing the need for coordinated and scalable service models that address barriers to care and social determinants of health. Interested applicants can apply for grants with an award ceiling of $459,000, with submissions due by March 19, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-059.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at testing innovative care models that integrate HIV, addiction, and primary care services. This initiative seeks to address gaps in comprehensive health service delivery for individuals at heightened risk for HIV or living with HIV and substance use disorders, emphasizing the need for replicable and sustainable interventions. The program is critical for enhancing service delivery to vulnerable populations and aligns with national public health goals to combat the HIV epidemic in the United States. Interested applicants can apply for a share of the $2 million funding by March 20, 2025, and should direct inquiries to grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html for more details.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.